Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

MDXG - Mimedx Group Inc


IEX Last Trade
6.85
0.160   2.336%

Share volume: 2,194,989
Last Updated: Fri 30 Aug 2024 09:59:55 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology): 0.21%

PREVIOUS CLOSE
CHG
CHG%

$6.69
0.16
2.39%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
54%
Profitability 66%
Dept financing 11%
Liquidity 50%
Performance 54%
Company vs Stock growth
vs
Performance
5 Days
-0.87%
1 Month
-9.88%
3 Months
-3.93%
6 Months
-16.59%
1 Year
-7.07%
2 Year
80.00%
Key data
Stock price
$6.85
P/E Ratio 
10.90
DAY RANGE
N/A - N/A
EPS 
$0.56
52 WEEK RANGE
$5.57 - $9.27
52 WEEK CHANGE
-$0.11
MARKET CAP 
1.004 B
YIELD 
N/A
SHARES OUTSTANDING 
146.809 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
10/28/2024
BETA 
1.41
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$764,350
AVERAGE 30 VOLUME 
$744,794
Company detail
CEO:
Region: US
Website: mimedx.com
Employees: 863
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

mimedx® is an industry leader in advanced wound care and a therapeutic biologics company developing and distributing human placental tissue allografts with patent-protected processes for multiple sectors of healthcare. the company processes the human placental tissue utilizing its proprietary purion® process methodology, among other processes, to produce allografts by employing aseptic processing techniques in addition to terminal sterilization. mimedx has supplied more than two million allografts, through both direct and consignment shipments. for additional information, please visit www.mimedx.com.

Recent news